Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Takeda Pharmaceutical Company Limited is a global biopharmaceutical leader based in Japan, specializing in the development of innovative medicines in areas such as oncology, gastroenterology, and neuroscience. Its competitive position is bolstered by a diverse pipeline of over 40 late-stage assets and a strong presence in key markets including the U.S., Japan, and Europe.
Takeda generates revenue primarily through the sale of prescription pharmaceuticals, leveraging its strong R&D capabilities to bring innovative therapies to market. The company benefits from pricing power in specialty drugs, particularly in oncology and rare diseases, where competition is limited and demand is high.
FDA approvals for key pipeline drugs such as TAK-003 for dengue fever
Market penetration and sales growth in the U.S. and EU for existing oncology therapies
Strategic partnerships or acquisitions that enhance the product pipeline
Regulatory changes impacting drug pricing and reimbursement policies
Regulatory changes that could impact drug approval processes or pricing
Technological disruption in drug development or delivery methods
Increased competition from generic drug manufacturers as patents expire
Emerging biotech firms with innovative therapies that could capture market share
Moderate financial risk due to relatively low ROE of 2.6%, indicating potential challenges in generating shareholder returns
Potential liquidity risks associated with high R&D expenditures
moderate - Takeda's performance is somewhat tied to overall healthcare spending, which can be influenced by economic cycles and consumer spending patterns.
Interest rates affect Takeda primarily through the cost of capital for R&D investments and potential impacts on consumer spending related to healthcare. Higher rates could lead to increased financing costs, but the demand for essential pharmaceuticals tends to remain stable.
minimal - Takeda's debt levels are manageable with a debt/equity ratio of 0.63, indicating a solid balance sheet and limited reliance on credit markets.
growth - due to its robust pipeline and potential for significant revenue growth from new product launches.
moderate - historical volatility is manageable, reflecting the stability of pharmaceutical revenues.